David van Dijk
Founder/CEOCo-Founder & CEO of CellType (W26). Yale Professor, 11,000+ citations. Built biological foundation models with Google. Building the agentic drug company.
Founder profile As recorded 2026-09-15
Browser storage is unavailable. Keep this page open and export your collection before leaving.
Biotech pharma
CellType
Overview
CellType is building an agentic drug company. AI agents that run the full drug discovery pipeline on top of biological foundation models that simulate human biology. Our core technology, developed with Google DeepMind, has already discovered and validated a new cancer treatment signal. We’re working with Top 10 pharma.
Company description As recorded 2026-11-08
Founders & team
Previously Contextual Bio
Company history As recorded 2026-11-08
Ivan Vrkic
Founder/CTOCo-Founder @ CellType (W26). ML @ Yale & EPFL. Building the next-generation agentic drug company. Co-developed our core technology Cell2Sentence at Yale and published at ICML. Previously led large-scale foundation model training in industry and built software to control CERN's Large Hadron Collider.
Founder profile As recorded 2026-09-15
5team members reported
Source-reported As recorded 2026-09-15
Founded 2025 · Source
News & product activity
Cohort membership
Winter 2026Winter 2026
Original evidence ↗Sources & observations
Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedNew York City, NY, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented
Source-based assessment · automated evidence rules
The latest capture is empty, blocked or a parked website.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-08
- Product visualsNot documented
- Founders & originsTeam information
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2026 Q1 (quarter only)
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
Similar businesses
Our autonomous biodefense capabilities ensure validated point-of-care diagnostics for emerging biological threats are developed in days, not 12+ months.
Founders
- Founded
- 2024
- Team
- 3 people
Same product type · AI agent
Turn weeks of manual research into answers in minutes. Powered by AI agents, backed by experts.
Customers · Founders · Product
- Founded
- 2024
- Team
- 3 people
Same product type · AI agent
An AI-maximalist pharma platform. We use agents to buy drugs, run clinical trials, and sell for a profit. 10x faster and 20x leaner than incumbents. Sourcing Agent: Mines public/private databases and unstructured global data to…
Founders · Origins · Product
- Founded
- 2025
- Team
- 4 people
Same product type · AI agent
Delineate creates models from the totality of available evidence — in any therapeutic area — so development, regulatory, and commercial teams act on quantitative evidence in a fraction of the time.
Founders · Product
- Founded
- 2024
- Team
- 20 people
Same product type · AI agent
Enjamb is the multiplayer AI workforce for biopharma. It connects to the software your company runs, including the lab systems and internal tools no other AI reaches, and it learns how your team works. Then it does that work in Slack or…
Founders · Product
- Founded
- 2025
- Team
- 2 people
Same product type · AI agent
Infera connects lab instruments to scientists and AI agents, so the work models are getting good at can reach the hardware in a lab.
Founders · Product · How it works
- Founded
- 2026
- Team
- 2 people
Same product type · AI agent